Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. Issue 9 (19th September 2019)

• Record Type: Journal Article
• Authors: Leader, Ross; Cowen, Jake; Rajeev, Surya Panicker
• Is Part Of: BMJ case reports. Volume 12:Issue 9(2019)
• Publication Date: 2019-09-19
• Subjects: Diabetes -- Drugs: Endocrine System -- Unwanted Effects / Adverse Reactions; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2019-231104
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Sodium glucose co-transporter-2 inhibitors (SGLT2-i) have become a popular therapeutic strategy in the management of hyperglycaemia in type 2 diabetes mellitus. The primary site of action of SGLT2-i is at the proximal renal convoluted tubule. They work by blocking SGLT2 receptors, sodium-dependent glucose co-transport molecules, which in turn prevents glucose reabsorption, facilitating glucosuria, improving glycaemic control as well as a moderate degree of weight loss. We report the case of a 51-year-old woman admitted to the acute medical unit with abdominal pain and vomiting, who was diagnosed with euglycaemic diabetic ketoacidosis secondary to recent initiation of an SGLT2-i medication (dapagliflozin). Clinicians should be aware of this rare side effect of SGLT2-i, to circumvent delays in patient management.